[¹⁸F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma

References

• Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710–725.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed.; IARC: Lyon 2017.
   Google Scholar
• Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647–1656.
   PubMed Web of Science ®Google Scholar
• Silkenstedt E, Linton K, Dreyling M. Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches. Br J Haematol. 2021;195(2):162–173.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34(12):1386–1394.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Validity of the Ann Arbor Staging Classification for the non-Hodgkin’s lymphomas. Cancer Treat Rep. 1977;61(6):1023–1027.
   PubMedGoogle Scholar
• Vercellino L, Cottereau AS, Casasnovas O, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135(16):1396–1405.
   PubMed Web of Science ®Google Scholar
• Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618–3626.
   PubMed Web of Science ®Google Scholar
• Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131(13):1456–1463.
   PubMed Web of Science ®Google Scholar
• Pike LC, Kirkwood AA, Patrick P, et al. Can baseline PET-CT features predict outcomes in advanced Hodgkin lymphoma? A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033). Hematol Oncol. 2017;35:37–38.
   PubMedGoogle Scholar
• Cottereau AS, Nioche C, Dirand AS, et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med. 2020;61(1):40–45.
   PubMed Web of Science ®Google Scholar
• Durmo R, Donati B, Rebaud L, et al. Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin lymphoma patients: a radio-genomic study. Hematol Oncol. 2022.
   PubMed Web of Science ®Google Scholar
• Albano D, Laudicella R, Ferro P, et al. The role of 18F-FDG PET/CT in staging and prognostication of mantle cell lymphoma: an Italian Multicentric Study. Cancers. 2019;11(12):1831.
   PubMed Web of Science ®Google Scholar
• Bailly C, Carlier T, Berriolo-Riedinger A, et al. Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET project. Haematologica. 2020;105(1):e33–e36.
   PubMedGoogle Scholar
• Albano D, Bosio G, Bianchetti N, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. Ann Nucl Med. 2019;33(7):449–458.
   PubMed Web of Science ®Google Scholar
• Mayerhoefer ME, Riedl CC, Kumar A, et al. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging. 2019;46(13):2760–2769.
   PubMed Web of Science ®Google Scholar
• Albano D, Treglia G, Gazzilli M, et al. 18F-FDG PET or PET/CT in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(7):422–430.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–3058.
   PubMed Web of Science ®Google Scholar
• Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–354.
   PubMed Web of Science ®Google Scholar
• Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41(6):1113–1122.
   PubMed Web of Science ®Google Scholar
• Tang X, Jafargholi Rangraz E, Coudyzer W, et al. Whole liver segmentation based on deep learning and manual adjustment for clinical use in SIRT. Eur J Nucl Med Mol Imaging. 2020;47(12):2742–2752.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346.
   PubMedGoogle Scholar
• Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–387.
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2010;329(14):987–994.
   Google Scholar
• Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–1219.
   PubMed Web of Science ®Google Scholar
• Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126(8):950–956.
   PubMed Web of Science ®Google Scholar
• Ceriani L, Milan L, Martelli M, et al. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood. 2018;132(2):179–186.
   PubMed Web of Science ®Google Scholar
• Akhtari M, Milgrom SA, Pinnix CC, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018;131(1):84–94.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schöder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130(20):2196–2203.
   PubMed Web of Science ®Google Scholar
• Karam M, Ata A, Irish K, et al. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Commun. 2009;30(10):770–778.
   PubMed Web of Science ®Google Scholar
• Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS Group. Eur J Nucl Med Mol Imaging. 2010;37(9):1633–1642.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou Y, Li L, et al. Current status and quality of radiomics studies in lymphoma: a systematic review. Eur Radiol. 2020;30(11):6228–6240.
   PubMed Web of Science ®Google Scholar